Pulmonary hypertension in newborns (PPHN) refers to abnormally high blood pressure in the pulmonary arteries and lungs of newborn infants. In infants with PPHN, the blood vessels that carry blood from the heart to the lungs are not relaxed as they should be after birth. This makes it much harder for the right side of the heart to pump blood to the lungs to receive oxygen. Babies with PPHN often appear blue in color due to the lack of oxygen. PPHN occurs in approximately 1 in 1,000-5,000 live births and can be life-threatening if not treated promptly.
Causes and Risk Factors for PPHN
There are several potential causes and risk factors for PPHN in newborns:
- Meconium aspiration syndrome: If an infant inhales meconium (fetal feces) during delivery, it can block blood vessels in the lungs.
- Sepsis: A bacterial infection in the bloodstream can lead to pulmonary hypertension.
- Congenital diaphragmatic hernia: A hole in the diaphragm that allows abdominal organs to move into the chest can compress the lungs.
- Congenital heart disease: Structural heart defects increase pressure and resistance in the pulmonary arteries.
- Preterm birth: Lungs that are not fully developed have a harder time transitioning from fetal to newborn circulation.
- Maternal conditions: Issues like preeclampsia, diabetes, or lupus in the mother raise PPHN risk.
Traditional Treatments for PPHN and Their Limitations
Standard initial treatment for PPHN involves ventilator support to oxygenate the baby's blood outside of the body. Medications such as prostacyclin and sildenafil are also frequently used to dilate pulmonary blood vessels. However, up to 30% of infants do not respond adequately to these conventional therapies. More invasive interventions like ECMO (extracorporeal membrane oxygenation) can be life-saving but carry risks of complications. A less risky alternative was needed to treat the most severe cases of PPHN.
The Discovery and Use of Inhaled Nitric Oxide
In the 1980s, researchers discovered that nitric oxide (NO) was produced naturally by the inner lining of blood vessels and functioned as a vasodilator. In 1991, clinical trials began using Inhaled nitric oxide to selectively dilate pulmonary vessels in newborns. Within minutes of exposure to iNO, signs of PPHN such as blueness and breathing difficulties improved dramatically.
Over 25 years of research has confirmed iNO as a safe and effective treatment for severe PPHN that does not respond to initial medical management. It works rapidly by relaxing pulmonary arteries, improving blood flow to the lungs, and increasing oxygen levels in the bloodstream. Multiple large clinical studies have established the benefits of iNO versus conventional treatment or placebo. Risks are generally low but may include mild oxidative effects if not delivered properly.
FDA Approval and Modern Use of iNO Therapy
In 1999, inhaled nitric oxide gas was approved by the FDA for use in term and near-term newborns with hypoxic respiratory failure caused by PPHN. It remains the standard-of-care treatment in NICUs for the most serious cases that do not improve on other interventions. As experience with iNO has grown, guidelines have expanded to allow use in mild-moderate PPHN or when ECMO is not available. While treatment is usually only needed for the first days or weeks of life, some long-term beneficial effects have been observed post-treatment. With proper dosing and delivery methods, iNO provides a targeted therapy with minimal side effects for a potentially fatal condition in newborns when administered promptly.
The development and clinical use of inhaled nitric oxide represents an important advancement in the treatment of persistent pulmonary hypertension of the newborn, one of the most serious complications that can occur at birth. Since its FDA approval over 20 years ago based on strong evidence from controlled studies, iNO has become established as a first-line option for severe PPHN unresponsive to standard medical care. Its selective pulmonary vasodilation properties allow it to rapidly improve oxygenation and reduce pressure in the lungs without negatively impacting the systemic circulation. While other supportive measures remain crucial, the introduction of iNO has greatly improved outcomes for newborns suffering from life-threatening pulmonary hypertension.
Select the language you're most comfortable with
About Author:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
